Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Windlas Biotech Limited is a vertically integrated Indian pharmaceutical company focused on formulation development, commercial GMP manufacturing and marketing across three strategic verticals: Generic Formulations CDMO, Trade Generics & Institutional sales, and Exports, with five WHO‑GMP plants in Dehradun and a recently commissioned injectable facility driving diversification across dosage forms.
Windlas delivered record revenues for the twelfth consecutive quarter: 9MFY26 revenue of Rs 666 crore and Q3FY26 revenue of Rs 233 crore, reflecting YoY growth of 19% and 20% respectively, driven by CDMO strength, rising injectable contributions and Plant‑2 extension benefiting utilization and volumes across core businesses.
The company owns intellectual property for ~99% of products it supplies as a CDMO, serves 757 customers and caters to 5,582 products, highlighting deep formulation expertise in complex generics and fixed‑dose combinations that create customer stickiness and higher margin mix, positioning Windlas Biotech as a go‑to partner for branded domestic formulators.
Balance sheet and cash generation are healthy: Windlas reported net‑debt free metrics, Rs 213 crore liquidity, positive operating cash flows (Rs 68 crore FY25) and strong return ratios (ROE ~25%, ROCE ~27%), supporting near‑term capex for Plant‑6 while maintaining financial discipline and the capacity to fund opportunistic investments.
Exports and trade generics are accelerating: exports grew 29% in 9MFY26 and 36% in Q3FY26 with penetration into RoW and semi‑regulated markets, while trade generics (400 brands) target tier‑2/3 expansion and institutional tenders such as Jan Aushadhi, offering multi‑front growth levers beyond CDMO volumes.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,862 Cr
Low Risk
24.6
32.3
1.4
3.5
1,137.60
699.35
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Windlas Biotech Ltd (WINDLAS) is currently trading at 884.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Windlas Biotech Limited is a vertically integrated Indian pharmaceutical company focused on formulation development, commercial GMP manufacturing and marketing across three strategic verticals: Generic Formulations CDMO, Trade Generics & Institutional sales, and Exports, with five WHO‑GMP plants in Dehradun and a recently commissioned injectable facility driving diversification across dosage forms. Windlas delivered record revenues for the twelfth consecutive quarter: 9MFY26 revenue of Rs 666 crore and Q3FY26 revenue of Rs 233 crore, reflecting YoY growth of 19% and 20% respectively, driven by CDMO strength, rising injectable contributions and Plant‑2 extension benefiting utilization and volumes across core businesses. The company owns intellectual property for ~99% of products it supplies as a CDMO, serves 757 customers and caters to 5,582 products, highlighting deep formulation expertise in complex generics and fixed‑dose combinations that create customer stickiness and higher margin mix, positioning Windlas Biotech as a go‑to partner for branded domestic formulators. Balance sheet and cash generation are healthy: Windlas reported net‑debt free metrics, Rs 213 crore liquidity, positive operating cash flows (Rs 68 crore FY25) and strong return ratios (ROE ~25%, ROCE ~27%), supporting near‑term capex for Plant‑6 while maintaining financial discipline and the capacity to fund opportunistic investments. Exports and trade generics are accelerating: exports grew 29% in 9MFY26 and 36% in Q3FY26 with penetration into RoW and semi‑regulated markets, while trade generics (400 brands) target tier‑2/3 expansion and institutional tenders such as Jan Aushadhi, offering multi‑front growth levers beyond CDMO volumes.
Over the past 52 weeks, Windlas Biotech Ltd has traded between a low of ₹699.35 and a high of ₹1,137.60. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Windlas Biotech Ltd has a market capitalization of approximately 1,861.57. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Windlas Biotech Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.61 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,861.57 Cr, Windlas Biotech Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Windlas Biotech Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Windlas Biotech Ltd is 24.61. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discovery themes featuring this stock
Bearish
7
Neutral
3
Bullish
4
Bearish
9
Neutral
3
Bullish
34
Bearish
2
Neutral
0
Bullish
30
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
358.30 | 2,226 Cr | -298.58 | 2.69 | 0.00 | -5.71 | -5.58 | -0.65 | ||
469.95 | 2,150 Cr | 86.55 | 4.58 | 0.00 | 0.00 | 0.00 | 0.00 | ||
196.45 | 1,982 Cr | -15.59 | 2.02 | 0.09 | -11.28 | -2.11 | -4.64 | ||
771.55 | 1,862 Cr | 24.61 | 3.49 | 0.65 | 12.60 | 16.43 | 8.20 | ||
473.50 | 1,770 Cr | -98.49 | 1.42 | 0.00 | 0.51 | 5.47 | -0.83 | ||
1747.00 | 1,701 Cr | 32.08 | 5.88 | 0.00 | 16.91 | 18.84 | 11.83 | ||
569.75 | 1,652 Cr | 40.47 | 4.83 | 0.80 | 16.57 | 22.53 | 13.16 | ||
| Median: 7 Co. | — | 473.50 | 1,862 Cr | 24.61 | 3.49 | 0.00 | 0.51 | 5.47 | 0.00 |
Share Buyback
Windlas Biotech will buy back 470,000 equity shares (face value INR 5) at INR 1,000 per share via a proportionate tender offer; public announcement published Apr 20, 2026 and board approved Apr 17, 2026.
Share buyback
Board approved buyback of up to 470,000 equity shares at INR 1,000/share (max INR 47,00,00,000), ~2.23% of equity; will be via tender offer excluding promoters; record date set as April 24, 2026.
Share Buyback
Board approved buyback of up to 470,000 equity shares at INR 1,000/share (max INR 47.00 crore) via tender offer excluding promoters; record date April 24, 2026; 15% reserved for small shareholders; manager appointed.
Share Buyback
Windlas Biotech's board approved a tender‑offer buyback of up to 470,000 equity shares (2.23% of paid‑up capital) at ₹1,000/share (max ₹47.00 crore); record date fixed as Apr 24, 2026; promoters will not participate.
